Strona 2 - Najlepsi lekarze do leczenia tymomy – TOP 59 lekarzy

Dr Yildiz specjalizuje się w leczeniu grasiczaka oraz nowotworów neuroendokrynnych, a wyniki jego licznych badań zostały opublikowane w międzynarodowych czasopismach medycznych.

• Opublikował ponad 17 prac naukowych na temat rzadkich schorzeń onkologicznych
• Posiada ekspercką wiedzę w diagnozowaniu i leczeniu złożonych przypadków grasiczaka
• Pracuje w Szpitalu Uniwersyteckim Medipol Mega — wiodącym centrum onkologii

Profesor Ondzhel specjalizuje się w chirurgii onkologicznej, ze szczególnym uwzględnieniem raka jelita grubego i odbytnicy. Wykonuje złożone zabiegi w Szpitalu Uniwersyteckim Medipol Mega.

• Odbył staż w Cleveland Clinic – wiodącym ośrodku chirurgii kolorektalnej
• Proktolog certyfikowany przez Komisję Europejską z ponad 25-letnim doświadczeniem
• Publikuje badania na temat gruczolakoraka odbytnicy oraz resekcji wielonarządowych w chorobach nowotworowych
• Kieruje Oddziałem Chirurgii na Uniwersytecie Medipol w Stambule
• Jest członkiem założycielem Eurazjatyckiego Stowarzyszenia Technologii Kolorektalnych

Dr Alemdar specjalizuje się w leczeniu grasiczaka i posiada bogate doświadczenie w dziedzinie onkologii klinicznej zdobyte w czołowych tureckich szpitalach.

• Ukończył szkolenie na Uniwersytecie Akdeniz — wiodącej placówce medycznej w Turcji
• Posiada ponad 15-letnie doświadczenie w onkologii i chorobach wewnętrznych
• Pracuje w kompleksie szpitalnym Medical Park Antalya, który jest wyposażony w zaawansowaną aparaturę do leczenia nowotworów
• Jest członkiem Tureckiego Towarzystwa Onkologii Klinicznej

Prof. dr hab. Wolfgang Köstler jest czołowym ekspertem w dziedzinie celowanych terapii nowotworowych, posiadającym ponad dwudziestoletnie doświadczenie w onkologii klinicznej.

• Specjalizuje się w leczeniu raka piersi oraz nowotworów ginekologicznych
• Zastępca kierownika Kliniki Onkologii Uniwersytetu Medycznego w Wiedniu
• Koncentruje się na indywidualizowanej systemowej terapii nowotworów oraz immunoterapii
• Publikuje prace badawcze na temat rozwoju biomarkerów i biologii nowotworów

Prof. Walter Klepetko zapoczątkował pierwsze w Austrii przeszczepy płuc i stworzył jeden z czołowych w Europie programów chirurgii klatki piersiowej na Uniwersytecie Medycznym w Wiedniu.

• Ponad 40 lat specjalizacji w złożonej onkologii klatki piersiowej i transplantacji płuc
• Były Kierownik Kliniki Chirurgii Klatki Piersiowej Uniwersytetu Medycznego w Wiedniu
• Opracował zaawansowane techniki małoinwazyjne w leczeniu nowotworów klatki piersiowej
• Uznany ekspert w prowadzeniu przypadków wysokiego ryzyka i złożonych resekcji

Profesor Keil specjalizuje się w zaawansowanych technikach obrazowania w celu precyzyjnej diagnostyki grasiczaka w Centrum Medycznym w Solingen.

• Ukończył z wyróżnieniem Uniwersytet Juliusza i Maksymiliana w Würzburgu.
• Ekspert w dziedzinie diagnostyki MRI, TK oraz USG.
• Lekarz kierujący oddziałem radiologii diagnostycznej i zabiegowej od 2022 roku.
• Kształcił się pod okiem uznanych radiologów w Niemczech.
• Oferuje pełen zakres usług z obszaru radiologii zabiegowej.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Ponad 30-letnie doświadczenie w immunologii – dr Jaunalksne specjalizuje się w wiroterapii, nowatorskiej dziedzinie leczenia grasiczaka.

• Kieruje Centrum Immunologii Klinicznej w Klinicznym Szpitalu Uniwersyteckim im. Paula Stradinsa
• Ukończyła Ryski Instytut Medyczny oraz odbyła staż w zakresie chorób wewnętrznych
• Skupia się na innowacyjnych podejściach immunologicznych

Doc. dr Nail Paksoy zdobywał doświadczenie w Instytucie Onkologii Uniwersytetu Stambulskiego oraz w szpitalu Medipol Bahçelievler. W swojej praktyce koncentruje się na leczeniu grasiczaka oraz innych nowotworów klatki piersiowej.

• Posiada certyfikat ESMO w dziedzinie onkologii klinicznej od 2022 roku
• Jest autorem badań nad rzadkimi nowotworami klatki piersiowej, publikowanych w międzynarodowych czasopismach naukowych
• Uczestniczył w 8 międzynarodowych badaniach klinicznych nad nowoczesnymi terapiami antynowotworowymi
• Specjalizuje się w stosowaniu immunoterapii oraz terapii celowanej

Dr Felix Dobritoiu stosuje nowoczesne techniki małoinwazyjne, takie jak chirurgia robotyczna (da Vinci Xi) oraz wideotorakoskopia jednoportowa (uniportal VATS), w leczeniu grasiczaka w Ponderas Academic Hospital.

• Specjalizuje się w chirurgii klatki piersiowej i posiada doświadczenie w złożonych resekcjach śródpiersia
• Wykonuje niewielkie nacięcia w celu przyspieszenia rekonwalescencji i zmniejszenia bólu pooperacyjnego
• Przeprowadza zabiegi bez pooperacyjnego drenażu opłucnej, gdy jest to możliwe
• Przeszedł szkolenie w zakresie zaawansowanych technik, w tym procedury Nussa

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Amr Mahmoud Al Demery is a consultant thoracic surgical oncologist with 12 years of experience. He holds an M.B.B.Ch from Kasr El-Aini, Cairo University (2007). He earned a Master’s in Surgical Oncology in 2014 and a Doctorate in Surgical Oncology in 2019 from the National Cancer Institute, Cairo University. He is a Member of the Royal College of Surgeons of England (MRCS, 2014). He speaks English and Arabic.

His practice includes the assessment, diagnosis, and surgical treatment of thoracic cancers. He performs bronchoscopy, thoracoscopy, and mediastinoscopy. He carries out lung resections, including wedge resection, lobectomy, bilobectomy, and pneumonectomy. He also performs esophageal resection with reconstruction and pleural decortication. His work includes thymectomy and mediastinal lymph node dissection. He performs chest wall and diaphragmatic tumor resection with reconstruction.

He served as Resident, Assistant Lecturer, and Lecturer of Surgical Oncology at the National Cancer Institute, Cairo University. He is a consultant in thoracic surgical oncology at Dar El-Salam, Tanta, Damanhour, and Shefaa Al Orman Cancer Centers. He is a member of the Egyptian Society of Surgical Oncology. He is a cofounder and member of the Egyptian Society of Respiratory Neoplasms.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.